anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention discloses pharmaceutical composition for controlled release regarding toxic active compounds, in particular, bioactive proteins from class of interferons. Composition contains bio-degradable block-copolymer made of poly(ethyleneglycol)terephthalate (PEGT) in amount from 50 to 95%, and poly(butyleneterephthalate) (PBT). Agent may be represented as injection microparticles, injection liquid, capable of independent gel or solid implant formation. Besides, invention provides a pharmaceutical set, including specified composition, methods of composition making and pharmaceutical versions of its application. ^ EFFECT: invention provides for initial release within 4 hours of not more than approximately 10% of included amount of one or more alpha-interferons and at least 80% of one or more alpha-interferons are released in monomer non-aggregated form. ^ 31 cl, 8 ex, 2 dwg
This study aimed to assess the consumption of ultra-processed foods (UPF) and identify their association with obesity and abdominal obesity in adult women of reproductive age living in situations of social vulnerability in Maceió, Northeastern Brazil. This was a cross-sectional study carried out between October 2020 and May 2021. An anthropometric evaluation was carried out to assess obesity and abdominal obesity. A dietary assessment was also conducted using a 24-h food recall to determine the calorie intake from UPF. To estimate intra-individual variability in food consumption, the probabilistic Multiple Source Method was used. These data in the form of tertiles were used to analyse the association between the consumption of UPF and obesity and abdominal obesity. Logistic regressions were used to analyse the association. A directed acyclic graph (DAG) was created for this analysis. This study included 1702 women of which 53.7% were 31 years old or older, and 74.2% lived in poverty. It identified that 36.5% and 38.1% of the women had obesity and abdominal obesity, respectively, and that an average of 33.8% of calories consumed came from UPF. In the analysis of association guided by the DAG, it was observed that women with a high-calorie intake from UPF had a 1.3 times higher probability of being obese. It was also observed that women with a moderate and high-calorie intake from UPF were 1.4 and 1.3 times more likely, respectively, to have abdominal obesity. Thus, it can be concluded that socially vulnerable women in Brazil have a relatively high consumption of UPF and that this condition increases the probability of obesity in this population group.
The 10-year MOF probability and the 10-year HF probability were calculated using the FRAXs of different regions (mainland China, Hong Kong, Taiwan, and Asia-America). Subjects were deemed as high-risk for osteoporotic fracture if the 10-year probability of MOF was ≥20% or the 10-year probability of HF was ≥3%.
A herbal medicine acne patch includes a carrier. The carrier has a first layer and a second layer combined by a surface of each other. The first layer has a porous structure; the second layer has a compact structure. The Second layer is more adhesive than the first layer. The carrier is provided with an anti-acne compound formula with the content thereof chosen from the group consisting of: a cortex phellodendri extract with a concentration from 1 to 2mg/ml, a centellae herba extract with a concentration between 1 to 3mg/ml, a polygonum cuspidatum extract with a concentration from 1 to 2 mg/ml, a pomegranate rind extract with a concentration between 0.1 to 1mg/ml, and a chamomile extract with a concentration between 0.1 to 1mg/ml. The contents of the compound formula are natural ingredients, capable of efficiently suppressing bacterial and facilitating the healing process of wound.
Participants who sign informed consents for both the main study and the optional 111In-PSMA-Trillium and Tris-POC Imaging Substudy. 111In-PSMA-Trillium and Tris-POC Imaging Substudy participants are not eligible for the 225Ac-PSMA-Trillium Imaging and Dosimetry Substudy or for the dense-PK sub-cohort in dose expansion. Each substudy participant will enter the 111In-PSMA-Trillium and Tris-POC Imaging Substudy period after completing a shortened screening period and before starting study treatment with 225Ac-PSMA-Trillium.
The invention provides a nano-preparation for local and systemic fat reduction and application thereof. The nano preparation consists of an oil phase and a water phase. The oil phase is composed of triglyceride membrane material, vitamin E as oxidative stress inhibitor, UPR pathway inhibitor, etc., and the water phase is composed of vitamin C deionized water solution. The nano preparation weakens the adipogenic differentiation of precursor cells and the oxidative stress and endoplasmic reticulum stress which are necessary in the maturation process of lipid accumulation of fat cells by encapsulating the endoplasmic reticulum stress inhibitor in a carrier containing the oxidative stress inhibitor, thereby greatly reducing the source of new fat and inhibiting the overgrowth of the existing fat cells, and achieving the purpose of efficiently, safely and slimming. The weight-reducing effect can realize local and/or systemic fat reduction with different purposes according to different administration modes, administration sites and administration doses. In addition, it has certain effect on preventing/treating fatty liver. The invention has reasonable design, simple preparation, safety, high efficiency and easy popularization.
Standard management. Patients will be kept at normothermia throughout the procedure (\>36oC).
The chemical structure of the luteinizing hormone releasing hormone (LHRH) was elucidatd in 1971. Since then, a very large number of international investigators synthesized more than 100 monosubstituted and about 14 disubstituted analogs of LHRH. All of these analogs were synthesized from natural amino acids having the L-configuration. Not one of these approximately 114 analogs showed agonist activity equivalent to that of LHRH. Two of the 114 were about 60% as active, and neither one has had any utility. We have investigated the six individual L-amino acids which occur in positions 5, 7, and 8 of the four naturally occurring LHRH's which exist in porcine/ovine, salmon, and chicken tissue. There are a total of 16 peptides with these structural features, and we have discovered that not only one but five of these peptides are not only equivalent in certain assays in activity to LHRH, but that two of the five are surprisingly superior to LHRH in activity, and that two of the five have a unique and unpredictable dissociation of activity for the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). These five peptides are: A. p-Glu His Trp Ser His Gly Leu Arg Pro Gly-NH2, B. p-Glu His Trp Ser His Gly Trp Arg Pro Gly-NH2, C. p-Glu His Trp Ser His Gly Trp Gln Pro Gly-NH2, D. p-Glu His Trp Ser His Gly Trp Leu Pro Gly-NH2, E. p-Glu His Trp Ser Tyr Gly Trp Arg Pro Gly-NH2, Peptide C might be the naturally occurring as FSHRH, because of its dissociated release of LH and FSH. The discovery for the first time of decapeptides with L-amino acids equal to or more potent than LHRH was based on about 14 years of background. Our new peptides are particularly useful in medical fields for pituitary stimulation and inhibition, for enhancement or inhibition of fertility in humans and animals, for the therapy of hormone-dependent tumors, for special effects on sexual behavior in humans and animals, and for design of new categories of superagonists and antagonists. Extrapituitary effects by these new peptides may be observed on the central nervous system or reproductive organs of humans and animals that are different from those of LHRH. The latter will be especially true if some of these new peptides are found to be native peptides such as FSH-RH or the LHRH-like peptides that have been detected in the gonads that are yet to be identified. The reason for believing this projection is possible is that some of these peptides have high or unique LH and FSH releasing activity in the LHRH radioreceptor assay, as exemplified by the biological activities of peptide C.
Women have constituted the fastest-growing group of persons with new AIDS diagnoses for several years. The need to develop and evaluate interventions to reduce the incidence of HIV infection among women is urgent. The behavioral intervention method tested in this study integrates elements from diverse theories and empirical evidence for women to feel empowered to use methods of protection against disease. Although the overall objective of the study intervention is to reduce the risk of HIV infection through sexual contact, the intervention must also address drug usage among women.

Women are randomized in a 1 to 1 ratio to either the intervention or control condition. The Intervention Group participates in 4 group sessions over the course of 1 month and then in an additional reunion session approximately 1 month after the 4th group session. Sessions are 2.5 hours long and include 6 to 10 participants. The sessions involve talking about HIV, ways to avoid HIV, and ways women can support each other. All participants complete a short-term assessment visit 1 week after the 4th group intervention session. The Control Group does not participate in group sessions. All participants are paid for their time and effort.
KEPPRA may cause coordination difficulties.

In controlled clinical studies in adult patients with partial-onset seizure studies, 3.4% of adult KEPPRA-treated patients experienced coordination difficulties, (reported as either ataxia, abnormal gait, or incoordination) compared to 1.6% of placebo-treated patients. A total of 0.4% of patients in controlled clinical studies discontinued KEPPRA treatment due to ataxia, compared to 0% of placebo-treated patients. In 0.7% of KEPPRA-treated patients and in 0.2% of placebo-treated patients, the dose was reduced due to coordination difficulties, while one of the KEPPRA-treated patients was hospitalized due to worsening of pre-existing ataxia. These events occurred most frequently within the first 4 weeks of treatment.

Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on KEPPRA to gauge whether it could adversely affect their ability to drive or operate machinery.
BACKGROUND AND AIM: An increasing amount of research has indicated obesity greatly affects individuals with overactive bladder (OAB). However, traditional anthropometric methods present challenges in accurately assessing the likelihood of OAB. Hence, this study's objective was to identify the correlation between the body roundness index (BRI) and OAB.
METHODS: The research included 12,401 individuals who participated in the National Health and Nutrition Examination Survey spanning 2005-2018. The correlation between BRI and OAB was explored by using weighted multiple logistic regression and weighted restricted cubic spline (RCS). Subgroup analyses showed the associations based on different population types. The study also analyzed the predictive capability of various anthropometric indices, including BRI, body mass index, waist circumference, and weight, in assessing the likelihood of OAB through Receiver-operating characteristic (ROC) curves.
RESULTS: An independent positive correlation between OAB and BRI was identified after adjusting for potential confounders in weighted multivariate logistic models[odds ratio (OR) = 1.15, 95% confidence interval (CI), 1.12-1.17]. Weighted RCS analysis found a positive dose-response correlation between OAB and BRI. The effect size of BRI on OAB remained stable across all prespecified subgroups (all P for interactions > 0.05). In ROC analysis, BRI showed better discriminatory ability for OAB compared with other anthropometric measures for both genders (all P < 0.01). The best BRI cutoff for predicting OAB was lower for men (5.151) than for women (5.383), suggesting that men were more susceptible to changes in BRI than women.
CONCLUSIONS: This study demonstrated that a raised BRI is correlated with a higher likelihood of OAB. Due to the effectiveness and non-invasiveness of BRI in predicting OAB, it is expected to become the preferred method for early detection and management strategies.
System and method for interfacing with a medical device. The system has a host device and a communication module. The host device has a user interface configured to input and display information relating to the interfacing with the medical device. The communication module is locally coupled to the host device and configured to communicate wirelessly with the medical device. The system, implemented by the host device and the communication module, is configured to communicate with the medical device with functions. The system, implemented by at least one of the host device and the communication module, has validation layers configured for use by users, each of the users having access to at least one of the validation layers based on a validation condition, each individual one of the functions being operational through the user interface only with one of the validation layers.
Bladder cancer (BC) is a common malignant tumor of urinary system, which can be divided into muscle-invasive BC (MIBC) and nonmuscle-invasive BC (NMIBC). The number of BC patients has been gradually increasing currently. At present, bladder tumours are diagnosed and followed-up using a combination of cystoscopic examination, cytology and histology. However, the detection of early grade tumors, which is much easier to treat effectively than advanced stage disease, is still insufficient. It frequently recurs and can progress when not expeditiously diagnosed and monitored following initial therapy for NMIBC. Treatment strategies are totally different for different stage diseases. Therefore, it is of great practical significance to study new biomarkers for diagnosis and prognosis. In this review, we summarize the current state of biomarker development in BC diagnosis and prognosis prediction. We retrospectively analyse eight diagnostic biomarkers and eight prognostic biomarkers, in which CK, P53, PPARγ, PTEN and ncRNA are emphasized for discussion. Eight molecular subtype systems are also identified. Clinical translation of biomarkers for diagnosis, prognosis, monitoring and treatment will hopefully improve outcomes for patients. These potential biomarkers provide an opportunity to diagnose tumors earlier and with greater accuracy, and help identify those patients most at risk of disease recurrence.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes valeramide and the valeramide-containing pharmaceutical composition made as standardized medicinal form that can be administrated by oral, injection, cutaneous or mucosa route. For anxiety decrease and soporofic effect doses of valeramide are 1.50-20 and 10-20 mg/kg body mass, respectively. When isovaleramide is used as an agent causing anxiolytic effect then nondesirable sedative-hypnotic effect is absent that will ensure to use its as a component of light psychotherapeutic drugs. Valeramide can be used for decrease of anxiety state and sleep inducing in human and domestic animals. EFFECT: enhanced effectiveness of valeramide. 13 cl, 4 dwg, 1 tbl, 2 ex
Arm 1 - Gastric cancer cohort (n=29 participants) will be treated with monotherapy called Crizotinib Oral Capsule \[Xalkori\] (250 mg b.d) taken on a continuous dosing schedule. One treatment cycle for Crizotinib is 28 days long.
The invention discloses rotenone cyclopropanecarboxamide. A chemical structural formula of rotenone cyclopropanecarboxamide is shown in the formula I, wherein R is selected from a hydrogen group, a methyl group or an ethyl group. The invention also discloses a preparation method of rotenone cyclopropanecarboxamide which is shown in the formula 1A and has a chemical name of 5,6-dimethoxy-N-[(R)-4-methoxy-2-(propenyl-2-yl)-2,3-dihydrobenzofuran-5-yl]-1,1a,2,7b-tetrahycyclopropa[c]benzofuran-7b-amide. The preparation method is characterized in that rotenone and oxygen-sulfur ylide undergo open-loop rearrangement, then are etherified by dimethyl sulphate, are oximated by hydroxylamine hydrochloride, and undergo Beckmann rearrangement in the presence of acetyl chloride as a catalyst. A crystal structure of rotenone cyclopropanecarboxamide shown in the formula 1A is characterized in that the crystal structure belongs to a triclinic system and a space group P1. The invention also discloses a use of rotenone cyclopropanecarboxamide in preparation of a drug for treating the human lung cancer or the human liver cancer.
An integrated lipoaspirate processing system is disclosed for mechanically processing adipose tissue into a therapeutic material that, in some embodiments, may be directly injected into a subject. The system includes an emulsification device that is used to emulsify the lipoaspirate sample. The emulsified lipoaspirate is then filtered by a microfluidic filtration device. The filtrate of the microfluidic filtration device is then processed in a microfluidic dissociation device. The integrated platform or system helps standardize hydrodynamic processing of lipoaspirate by producing predictable and consistent shear forces and enabling automation in clinical settings. Progressive processing through multiple devices in series enables optimal recovery of regenerative cells while preventing clogging.
PROBLEM TO BE SOLVED: To obtain the subject formulation for removing salmonella bacteria from bovine intestinal tracts by including a lactobacillus, a butyric acid bacterium and a saccharogenic bacterium as active ingredients. SOLUTION: This formulation contains the mixture of three kinds of live bacteria comprising a lactobacillus, a butyric acid bacterium and a saccharogenic bacterium. The lactobacillus includes Streptococcus faecalis T-110 (referred to as SF), is a gram-positive facultative anaerobic micrococcus, and has characters comprising a high lactic acid-producing ability and a large proliferation rate. The butyric acid bacterium includes Clostridium butyricum TO-A (referred to as CB), is a gram-positive strictly aerobic bacillus bacterium, has a spore-forming ability, and produces a short chain fatty acid such as butyric acid or acetic acid. The saccharogenic bacterium includes Bacillus mesentericus TO-A (referred to BM), is a gram-positive aerobic bacillus bacterium, and produces an amylolytic enzyme. The three kinds of bacteria are preferably added in a SF:CB:BM ratio of 10:1:1.  The formulation is administered at each dose of 20-50 g for a calf or at each dose of 50-200 g for an adult cattle. The various syndromes of the cattle due to the salmonellosis are improved.
The present invention discloses antisense poly-2'-O-(2,4-dinitrophenyl) oligoribonucleotides which are capable of down regulating the expression of the RIα subunit of protein kinase A. An example is 5'-GGCUGCGUGCCUCCUCACUGG (named antisense poly-DNP RNA­21) or a sequence which has a one-base mismatch therewith. The antisense oligoribonucleotide can be synthesized by in vitro transcription followed by chemical derivatization. The base sequence of the oligoribonucleotides is complementary to that of nt 110 to 130 in RIα/PKA mRNA. The antisense poly-DNPRNA-21 was found to inhibit cell growth with IC50 values in the nanomolar range. These oligonucleotides can be used as effective anti-cancer agents.
The present invention relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol as an active ingredient and a health functional food composition for ameliorating somnipathy including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, do not cause tolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration, and do not cause side effects of a conventional agonist at the benzodiazepine binding site of the GABA-A receptor. The present invention also relates to a pharmaceutical composition for suppressing tolerance to or alleviating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient and a health functional food composition for suppressing tolerance to or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention can alleviate side effects of the agonist or can suppress tolerance to the agonist resulting from long-term administration. The present invention also relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol and an agonist at the benzodiazepine binding site of the GABA-A receptor as active ingredients. The pharmaceutical composition of the present invention uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to alleviate side effects of the agonist or suppress tolerance to the agonist resulting from long-term administration.
Memantine hydrochloride tablets are an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula:

The molecular formula is C12H21N•HCl and the molecular weight is 215.76. Memantine hydrochloride occurs as a fine white to off-white powder and is soluble in water.

Memantine hydrochloride is available as tablets. Memantine hydrochloride tablets are available for oral administration as capsule-shaped, film-coated tablets containing 5 mg and 10 mg of memantine hydrochloride. The tablets also contain the following inactive ingredients: microcrystalline cellulose/colloidal silicon dioxide, talc, croscarmellose sodium, and magnesium stearate. In addition, the following inactive ingredients are also present as components of the film coat: hypromellose, titanium dioxide, polyethylene glycol 400, FD&C yellow #6 and FD&C blue #2 (5 mg tablets), and hypromellose, titanium dioxide, macrogol/polyethylene glycol 400 and iron oxide black (10 mg tablets).
A system for measuring a glucose level in a blood sample includes a test strip and a meter. The test strip includes a sample chamber or other testing zone, a working electrode, a counter electrode, fill-detect electrodes, and an auto-on conductor. A reagent layer is disposed in the testing zone. The auto-on conductor causes the meter to wake up and perform a test strip sequence when the test strip is inserted in the meter. The meter uses the working and counter electrodes to initially detect the blood sample in the sample chamber and uses the fill-detect electrodes to check that the blood sample has mixed with the reagent layer. The meter applies an assay voltage between the working and counter electrodes and measures the resulting current. The meter calculates the glucose level based on the measured current and calibration data saved in memory from a removable data storage device associated with the test strip.